ICON Public Limited Company (ICLR) Earnings
ICON Public Limited Company is expected to report next earnings on July 29, 2026 (in NaN days), with a consensus EPS estimate of $2.55. ICLR has beaten EPS estimates in 6 of its last 12 reported quarters (average surprise +2.1% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jun 24, 2026 | $2.43 | $2.50 | +2.9% | $2.1B | +6.6% |
| Oct 22, 2025 | $3.28 | $3.31 | +0.9% | $2.0B | +1.5% |
| Jul 23, 2025 | $3.19 | $3.26 | +2.2% | $2.0B | +1.8% |
| Apr 30, 2025 | $3.11 | $3.19 | +2.6% | $2.0B | -0.3% |
| Feb 19, 2025 | $3.41 | $3.43 | +0.6% | $2.0B | +0.2% |
| Oct 23, 2024 | $3.85 | $3.35 | -13.0% | $2.0B | -0.3% |
| Jul 24, 2024 | $3.68 | $3.75 | +1.9% | $2.1B | -0.8% |
| Feb 21, 2024 | $3.44 | $3.46 | +0.6% | $2.1B | -1.2% |
| Oct 25, 2023 | $3.28 | $3.30 | +0.6% | $2.1B | -1.7% |
| Jul 26, 2023 | $3.08 | $3.11 | +1.0% | $2.0B | -1.6% |
| Feb 22, 2023 | $3.06 | $3.13 | +2.3% | $2.0B | -0.8% |
| Nov 2, 2022 | $2.93 | $3.00 | +2.4% | $1.9B | +0.4% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · June 24, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Commercial Strategy and Performance * Core strategic priorities: diversify large pharma sales channels, expand mid-size pharma penetration, and increase biotech RFP flow and win rates, all of which saw meaningful progress in Q1 * Q1 gross bookings hit $3.3 billion, flat sequentially from Q4 2025 and up 22% year-over-year; cancellations were $383 million, in line with Q4 2025's improved levels. Net business wins reached $2.88 billion, up 42% year-over-year, for a net book-to-bill ratio of 1.42x, with direct fee book-to-bill exceeding 1.3x * Win rates for large pharma and biotech full service sustained the step-up improvement seen in Q4 2025; therapeutic mix remains concentrated in oncology and cardiometabolic, with increased diversification in cardiometabolic indications including MASH, obesity, and kidney disease * Large pharma: secured a new central labs partnership with a top 5 pharma customer where ICON previously had limited labs business, driven by flexible delivery and long-standing strong performance in other service areas * Mid-size pharma: opportunity flow is up high teens year-over-year, with multiple strategic partnership discussions in progress; ICON secured a new partnership by displacing an incumbent large CRO in Q1 * Biotech: the evolved strategy of using consulting and early development projects to drive demand into Phase 2/3 continues to deliver, with sustained improved win rates and a good balance of new and repeat customers - Strategic Capability Expansions * Expanding the central laboratory facility in Singapore to grow lab offerings and accelerate regional growth in Asia * Launched a flagship oncology research site partnership with the Brian Moran Cancer Institute in the U.S. to address industry-wide patient recruitment gaps and expand access to oncology trials via a network of community-based cancer centers * Partnered with Microsoft to advance ICON's intelligence-led digital platform: developing the agentic AI layer for ICON's Orbis platform, deploying enterprise co-pilots to automate repetitive work and increase efficiency, and integrating frontier AI models to build domain-specific agents embedded in clinical development workflows - Financial Performance * Adjusted EBITDA was $317.7 million (15.6% margin), up 10 basis points sequentially, in line with prior guidance * Adjusted net income was $192.9 million, or $2.50 adjusted EPS; GAAP net income was $104.8 million, or $1.36 diluted EPS * Free cash flow was $136.2 million in Q1; net debt decreased to $2.6 billion, with a leverage ratio of 1.8x net debt to trailing 12-month adjusted EBITDA, reflecting a strong balance sheet * Returning capital to shareholders via share repurchases remains the top capital deployment priority, alongside targeted capability investments for future growth
Guidance
- Full year 2026 financial guidance is unchanged from prior updates: revenue is expected in the range of $7.85 billion to $8.15 billion, and adjusted diluted EPS is expected in the range of $10 to $11 - Management expects modest sequential adjusted EBITDA margin expansion throughout 2026, reaching a full year margin of ~16.5% at the guidance midpoint, driven by ongoing actions already in process - Q2 2026 adjusted EBITDA margin is expected to improve ~50 basis points from Q1 to ~16%, with continued incremental margin expansion in the second half of 2026 - Drivers of full year margin improvement include: (1) an expected improvement in business mix, with growing direct fee full service revenue as a proportion of total revenue, mitigating the current margin pressure from faster FSP growth; (2) disciplined cost management actions that will deliver incremental benefits in the second half of 2026 - The full year guidance assumes a book-to-bill ratio of ~1.0x for the remainder of 2026; stronger than expected commercial traction would primarily act as a tailwind for 2027 results rather than 2026 - The 2026 adjusted effective tax rate is still expected to be approximately 17% - Share repurchases are expected to resume in Q3 2026, after the release of Q2 results, as the company has been in a closed period following a delay in year-end result publication
Segment performance
Overall consolidated Q1 2026 revenue was $2.0 billion, up 0.9% year-over-year (down 1.9% constant currency). The call does not break out separate financial performance metrics (absolute revenue or revenue contribution percentage) for individual product segments, only notes that strong Q1 gross bookings were broad-based, with particularly strong RFP flow in pharma full service and development solutions, and sequentially higher double-digit RFP flow growth in biotech full service. FSP revenue has been growing faster than full service direct revenue, which has seen a slight recent decline. Customer concentration remains stable: top 5 customers accounted for 25% of Q1 revenue, top 10 accounted for 40.3%, and top 25 accounted for 63.4%.
Risks & headwinds
- Cancellations are inherently volatile on a quarterly basis; the exceptionally low cancellation rate seen in Q1 2026 ($383 million) is not expected to be the new steady state, with future run rates likely to be moderately higher, generally ranging between $500 million and $600 million per quarter - Pricing pressure remains an ongoing dynamic, with consistent customer demand for rate concessions and discounts quarter over quarter - Pass-through revenue is inherently volatile and difficult to forecast, which can impact actual margin performance relative to guidance ranges - Conversion of recent strong bookings into recognizable revenue takes time, with most incremental revenue from recent wins expected to flow to the P&L in 2027 rather than 2026 - Forward-looking statements are inherently uncertain, and actual results may differ materially from expectations due to unforeseen risks and uncertainties, which are detailed in the company's most recent Form 20F filing
Analyst Q&A
Q: Why did the spread between backlog and performance obligations widen in Q1? Is this from uncontracted new awards rather than realizable value adjustments? /
A: The wider spread is due to two factors: the quarter's very strong book-to-bill performance, and typical Q1 seasonality which means Q1 is generally a weaker quarter for contract signings. Management expects Q2 will be a very strong quarter for signings, which will lead to a significant shift in this metric in the Q2 results. This spread does not reflect any adjustments to the realizable value of already contracted awards.
Q: What drove the lower-than-historical cancellations in Q4 2025 and Q1 2026, and what should we expect for Q2 cancellations? /
A: The exceptionally low Q1 cancellation rate is not materially driven by methodology changes; it is just a naturally low quarterly outcome. Management does not expect this low rate to hold as a baseline going forward, and Q2 cancellations will tick up moderately. Future cancellations will still be far lower than the concerning levels seen in prior periods, and a normal range of $500-$600 million per quarter is expected for a business of ICON's size.
Q: What is the quality of ICON's current opportunity pipeline, including contribution from labs and Phase 1/3 balance, and has the pricing environment changed? /
A: Management focuses on the quality and convertibility of pipeline opportunities rather than just raw volume, and the current pipeline is encouraging. Recent bookings have seen a meaningful skew towards higher-margin Phase 3 trials, and there is strong growth momentum for the labs business. Biotech pipeline quality has improved the most, with sustained higher RFP flow and win rates. The pricing environment is unchanged: it remains consistently competitive, with ongoing pressure for concessions, but ICON prioritizes profitable value-creating work over low-margin volume.
Q: What is driving the expected sequential margin improvement this year, and how confident is management in this trajectory? /
A: Q1 adjusted EBITDA margin of 15.6% was right in line with prior guidance, and no core expectations for full year margin have changed. Sequential improvement will come from two roughly equal contributors: improving business mix as higher-margin direct fee full service revenue grows through the back half of the year, and incremental benefits from cost efficiency actions already in flight that will flow to the P&L in the second half. Management expects Q2 margin will reach ~16%, a 50 basis point improvement from Q1, with full year margin reaching ~16.5% at the guidance midpoint.